Merestinib on Bone Metastases in Subjects With Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Bone Metastases|Breast Cancer
Interventions: DRUG: Merestinib
Sponsor: University of Utah
Collaborators: Eli Lilly and Company